title: Must only be reconstituted in the diluent solution provided
text: |
  Must only be reconstituted in the diluent solution provided
  |
  bet | 191/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Must only be reconstituted in the diluent solution provided. Draw up 10 mL of diluent into a syringe, inject into vial and mix to dissolve contents of vial.
  Draw up all of contents of the vial and return to the diluent vial (to make total of 50 ml of concentrated solution). Mix again. This solution now contains 10,000 nanograms/mL (10g/mL).
  Take ‘X’ mL of the concentrated solution and make up to 50 mL with the second vial of diluent.
  ‘X’ = 6 x Body Weight in kg
  Final dilution- 1mL/hr = 20nanogram/kg/min
  Administer infusion through 0.2 or 0.22micrometre in line filter
  NOTE: these instructions pertain to the Flolan™ brand only (pharmacy’s preferred supplier); if using Veletri™ brand follow specific dilution instructions for that brand (final concentration of solution and dosage remain the same)
  Stability :
  |
  The base solution is stable for 24 hours.
  |
  Storage :
  |
  Refrigerated, protect from light.
  |
  Incompatibility :
  |
  Use dedicated line as mixing with other fluids will reduce pH and make solution unstable
  |
  Serum Levels :
  |
  Not applicable
  |
  References:
  |
  Australian Injectable Drugs Handbook, 8th edition;
  Epoprostenol Sodium Monograph https://aidh.hcn.com.au/browse/e/epoprostenol_sodium
  National Institute for Health and Care Excellence, Pulmonary
  Hypertension in Neonates: Sildenafil, Evidence Summary, March 2016 https://www.nice.org.uk/advice/esuom51/chapter/Key-points-from-the-evidence
  AMH Children’s Dosing Companion, Epoprostenol July 2020
  https://childrens.amh.net.au/monographs/epoprostenol
  Australian Product Information Flolan (epoprostenol) powder
  for injection, GSK 2018 https://au.gsk.com/media/383858/flolan_injection_pi_011_approved.pdf
  5.Ainsworth, S; Neonatal Formulary 8th ed. 2020, Oxford University Press
  |
  Original version Date: 9/1/2014
  |
  Author: AK, JD
  |
  Current Version number: 2
  |
  Current Version Date: 29/10/2020
  |
  Risk Rating: Medium
  |
  Due for Review: 29/10/2025
  |
  Approved by: DTC
  |
  Approval Date: TBA
  |
  |
  | |